首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1563121

細胞和基因治療藥物生物製造的全球市場：依產品類型、階段、應用、最終用戶和地區的預測（~2032年）

Global Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type, By Usage, By Application, By End User And By Region - Forecast Till 2032

出版日期: 2024年08月10日 | 出版商:

Market Research Future | 英文 131 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

細胞和基因治療藥物生物製造的市場規模預計將從2022年的126億美元，2023年的139億美元，到2032年將成長到312億美元，預測期內年複合成長率為10.60%。推動市場成長的主要因素是細胞和基因治療藥物研究投資的增加。

細胞和基因治療藥物市場經歷快速成長，對製造解決方案不斷成長的需求推動細胞和基因治療生物製造市場。有希望的臨床試驗結果以及新型細胞和基因療法的批准推動增加生產量以滿足商業化要求的需求。市場的快速成長需要開發高效、可擴展且具有成本效益的生物製造流程和基礎設施。為了滿足對細胞和基因治療產品日益成長的需求，生物製造商投資自動化、一次性系統和封閉系統生物反應器等先進技術。

依地域的展望

由於多種因素，北美在該市場處於主導地位。首先，北美地區擁有蓬勃發展的製藥和生技公司生態系統，積極參與細胞和基因治療研發。其次，北美擁有完善的監管架構和促進市場成長的支持政策。

歐洲的細胞和基因治療生物製造市場擁有第二大市場佔有率，這要歸功於其優秀的勞動力。歐洲第二大市場佔有率歸因於多種因素，包括擁有優秀的勞動力、先進的基礎設施和完善的生物製藥行業。

估計2024年至2032年，亞太市場將經歷最快的成長。在研發增加的推動下，該地區的生物製藥產業經歷快速成長，特別是在細胞和基因治療領域。

本報告調查了細胞和基因治療藥物的全球生物製造市場，提供了市場的定義和概述，分析了市場成長的各種影響因素、市場規模的趨勢和預測，以及各個細分市場和地區。

Global Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type (Consumables, Equipment and Software Solutions), By Usage (Commercial Stage Manufacturing and Research Stage Manufacturing), By Application (Upstream Processing, Harvesting and Downstream Processing), By End User (Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations and Cell Banks) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

Market Overview

In 2022, the market size of cell and gene therapy biomanufacturing was estimated to be USD 12.6 billion. The Cell and Gene Therapy Biomanufacturing market industry is anticipated to witness a compound annual growth rate (CAGR) of 10.60% from USD 13.9 Billion in 2023 to USD 31.2 Billion by 2032 through the forecast period (2024-2032). The primary market drivers that are fostering market growth are the increasing investments in cell and gene therapy research.

The Cell and Gene Therapy Market is experiencing rapid growth, which is driving the Cell and Gene Therapy Biomanufacturing Market forward by increasing demand for manufacturing solutions. Given the promising clinical trial results and the approval of novel cell and gene therapies, there is a growing necessity to increase production in order to satisfy commercialization requirements. The development of efficient, scalable, and cost-effective biomanufacturing processes and infrastructure is required due to the exponential growth of the market. In response to the increasing demand for cell and gene therapy products, biomanufacturing companies are investing in advanced technologies, including automation, single-use systems, and closed-system bioreactors. Furthermore, the Cell and Gene Therapy Biomanufacturing Market is experiencing growth as a result of the market's expansion, which is fostering collaborations, partnerships, and investments in biomanufacturing capacity to address the swiftly changing cell and gene therapy landscape.

Market segment insights

Consumables, Equipment, and Software Solutions comprise the Cell and Gene Therapy Biomanufacturing Market segmentation, with respect to product type.

Based on usage, the market segmentation comprises Commercial Stage Manufacturing and Research Stage Manufacturing.

Based on application, the market segmentation comprises Upstream Processing, Harvesting, and Downstream Processing.

The Cell and Gene Therapy Biomanufacturing Market segmentation is based on the end user and includes Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks.

Regional Perspectives

The study offers market insights for North America, Europe, Asia-Pacific, and the Rest of the World by region. The Cell and Gene Therapy Biomanufacturing Market has been dominated by North America because of a variety of factors. Initially, the region is home to a thriving ecosystem of pharmaceutical and biotechnology companies that are actively involved in the research and development of cell and gene therapies. Secondly, the market growth is facilitated by the well-established regulatory frameworks and supportive policies for cell and gene therapy manufacturing in North America.

The second-largest market share in the European Cell and Gene Therapy Biomanufacturing market is attributed to the competent workforce. Several factors have contributed to Europe's acquisition of the second-largest market share in the Cell and Gene Therapy Biomanufacturing Market. The region is fortunate to have a skilled personnel, advanced infrastructure, and a well-established biopharmaceutical industry.

The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market is anticipated to experience the most rapid rate of growth from 2024 to 2032. The Cell and Gene Therapy Biomanufacturing Market is experiencing the highest compound annual growth rate (CAGR) in the Asia Pacific region because of diverse factors. Initially, the biopharmaceutical industry in the region is experiencing accelerated growth as a result of the growing investment in research and development, particularly in the fields of cell and gene therapy.

Major Players

Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and Others are the major players in the Cell and Gene Therapy Biomanufacturing market.

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. DEFINITION
2.2. SCOPE OF THE STUDY
- 2.2.1. RESEARCH OBJECTIVE
- 2.2.2. ASSUMPTIONS

2.2.3.LIMITATIONS

3. RESEARCH METHODOLOGY

3.1. OVERVIEW
3.2. DATA MINING
3.3. SECONDARY RESEARCH
3.4. PRIMARY RESEARCH
- 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2.BREAKDOWN OF PRIMARY RESPONDENTS

3.5. FORECASTING MODEL
3.6. MARKET SIZE ESTIMATION
- 3.6.1. BOTTOM-UP APPROACH
- 3.6.2. TOP-DOWN APPROACH
3.7. DATA TRIANGULATION
3.8. VALIDATION

4. MARKET DYNAMICS

4.1. OVERVIEW
4.2. DRIVERS
4.3. RESTRAINTS
4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS

5.1. VALUE CHAIN ANALYSIS
5.2. PORTER'S FIVE FORCES ANALYSIS
- 5.2.1. BARGAINING POWER OF SUPPLIERS
- 5.2.2. BARGAINING POWER OF BUYERS
- 5.2.3. THREAT OF NEW ENTRANTS
- 5.2.4. THREAT OF SUBSTITUTES
- 5.2.5. INTENSITY OF RIVALRY
5.3. COVID-19 IMPACT ANALYSIS
- 5.3.1. MARKET IMPACT ANALYSIS
- 5.3.2. REGIONAL IMPACT
- 5.3.3. OPPORTUNITY AND THREAT ANALYSIS

6. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE

6.1. OVERVIEW
6.2. CONSUMABLES
6.3. EQUIPMENT
6.4. SOFTWARE SOLUTIONS

7. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE

7.1. OVERVIEW
7.2. COMMERCIAL STAGE MANUFACTURING
7.3. RESEARCH STAGE MANUFACTURING

8. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION

8.1. OVERVIEW
8.2. UPSTREAM PROCESSING
8.3. HARVESTING
8.4. DOWNSTREAM PROCESSING

9. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER

9.1. OVERVIEW
9.2. LIFE SCIENCE COMPANIES
9.3. CONTRACT RESEARCH ORGANIZATIONS
9.4. CONTRACT MANUFACTURING ORGANIZATIONS
9.5. CELL BANKS

10. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY REGION

10.1. OVERVIEW
10.1. NORTH AMERICA
- 10.1.1. US
- 10.1.2. CANADA
10.2. EUROPE
- 10.2.1. GERMANY
- 10.2.2. FRANCE
- 10.2.3. UK
- 10.2.4. ITALY
- 10.2.5. SPAIN
- 10.2.6. REST OF EUROPE
10.3. ASIA-PACIFIC
- 10.3.1. CHINA
- 10.3.2. INDIA
- 10.3.3. JAPAN
- 10.3.4. SOUTH KOREA
- 10.3.5. AUSTRALIA
- 10.3.6. REST OF ASIA-PACIFIC
10.4. REST OF THE WORLD
- 10.4.1. MIDDLE EAST
- 10.4.2. AFRICA
- 10.4.3. LATIN AMERICA

11. COMPETITIVE LANDSCAPE

11.1. OVERVIEW
11.2. COMPETITIVE ANALYSIS
11.3. MARKET SHARE ANALYSIS
11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
11.5. COMPETITIVE BENCHMARKING
11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
- 11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT
- 11.7.2. MERGER & ACQUISITIONS
- 11.7.3. JOINT VENTURES
11.8. MAJOR PLAYERS FINANCIAL MATRIX
- 11.8.1. SALES & OPERATING INCOME,
- 11.8.2. MAJOR PLAYERS R&D EXPENDITURE.

12. COMPANY PROFILES

12.1. LONZA GROUP
- 12.1.1. COMPANY OVERVIEW
- 12.1.2. FINANCIAL OVERVIEW
- 12.1.3. PRODUCTS OFFERED
- 12.1.4. KEY DEVELOPMENTS
- 12.1.5. SWOT ANALYSIS
- 12.1.6. KEY STRATEGIES
12.2. THERMO FISHER SCIENTIFIC INC.
- 12.2.1. COMPANY OVERVIEW
- 12.2.2. FINANCIAL OVERVIEW
- 12.2.3. PRODUCTS OFFERED
- 12.2.4. KEY DEVELOPMENTS
- 12.2.5. SWOT ANALYSIS
- 12.2.6. KEY STRATEGIES
12.3. MERCK KGAA
- 12.3.1. COMPANY OVERVIEW
- 12.3.2. FINANCIAL OVERVIEW
- 12.3.3. PRODUCTS OFFERED
- 12.3.4. KEY DEVELOPMENTS
- 12.3.5. SWOT ANALYSIS
- 12.3.6. KEY STRATEGIES
12.4. WUXI APPTEC
- 12.4.1. COMPANY OVERVIEW
- 12.4.2. FINANCIAL OVERVIEW
- 12.4.3. PRODUCTS OFFERED
- 12.4.4. KEY DEVELOPMENTS
- 12.4.5. SWOT ANALYSIS
- 12.4.6. KEY STRATEGIES
12.5. CATALENT, INC.
- 12.5.1. COMPANY OVERVIEW
- 12.5.2. FINANCIAL OVERVIEW
- 12.5.3. PRODUCTS OFFERED
- 12.5.4. KEY DEVELOPMENTS
- 12.5.5. SWOT ANALYSIS
- 12.5.6. KEY STRATEGIES
12.6. SAMSUNG BIOLOGICS
- 12.6.1. COMPANY OVERVIEW
- 12.6.2. FINANCIAL OVERVIEW
- 12.6.3. PRODUCTS OFFERED
- 12.6.4. KEY DEVELOPMENTS
- 12.6.5. SWOT ANALYSIS
- 12.6.6. KEY STRATEGIES
12.7. FUJIFILM DIOSYNTH BIOTECHNOLOGIES
- 12.7.1. COMPANY OVERVIEW
- 12.7.2. FINANCIAL OVERVIEW
- 12.7.3. PRODUCTS OFFERED
- 12.7.4. KEY DEVELOPMENTS
- 12.7.5. SWOT ANALYSIS
- 12.7.6. KEY STRATEGIES
12.8. CHARLES RIVER LABORATORIES
- 12.8.1. COMPANY OVERVIEW
- 12.8.2. FINANCIAL OVERVIEW
- 12.8.3. PRODUCTS OFFERED
- 12.8.4. KEY DEVELOPMENTS
- 12.8.5. SWOT ANALYSIS
- 12.8.6. KEY STRATEGIES
12.9. CYTIVA
- 12.9.1. COMPANY OVERVIEW
- 12.9.2. FINANCIAL OVERVIEW
- 12.9.3. PRODUCTS OFFERED
- 12.9.4. KEY DEVELOPMENTS
- 12.9.5. SWOT ANALYSIS
- 12.9.6. KEY STRATEGIES
12.10. NOVASEP
- 12.10.1. COMPANY OVERVIEW
- 12.10.2. FINANCIAL OVERVIEW
- 12.10.3. PRODUCTS OFFERED
- 12.10.4. KEY DEVELOPMENTS
- 12.10.5. SWOT ANALYSIS
- 12.10.6. KEY STRATEGIES

13. APPENDIX

13.1. REFERENCES
13.2. RELATED REPORTS

簡介目錄圖表

LIST OF TABLES

TABLE 1 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 11 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 12 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 13 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 14 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 15 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 16 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 17 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 18 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 19 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 20 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 21 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 22 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 23 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 24 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 25 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 26 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 27 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 28 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 29 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 30 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 31 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 32 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 33 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 34 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 35 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 36 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 37 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 38 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 39 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 40 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 41 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 42 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 43 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 44 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 45 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 46 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 47 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 48 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 49 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 50 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 51 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 52 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 53 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 54 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 55 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 56 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 57 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 58 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 59 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 60 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 61 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 62 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 63 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 64 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 65 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 66 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 67 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 68 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 69 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 70 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 71 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 72 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 73 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 74 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 75 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 76 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 77 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 78 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 79 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 80 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 81 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 82 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 83 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 84 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 85 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 86 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 87 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 88 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 89 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 90 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET
FIGURE 4 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY PRODUCT TYPE,
FIGURE 5 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY USAGE,
FIGURE 6 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY APPLICATION,
FIGURE 7 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY END USER,
FIGURE 8 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 9 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 10 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 11 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 12 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 13 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 14 LONZA GROUP: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 LONZA GROUP: SWOT ANALYSIS
FIGURE 16 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
FIGURE 18 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 MERCK KGAA: SWOT ANALYSIS
FIGURE 20 WUXI APPTEC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 WUXI APPTEC: SWOT ANALYSIS
FIGURE 22 CATALENT, INC..: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 CATALENT, INC..: SWOT ANALYSIS
FIGURE 24 SAMSUNG BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 SAMSUNG BIOLOGICS: SWOT ANALYSIS
FIGURE 26 FUJIFILM DIOSYNTH BIOTECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 FUJIFILM DIOSYNTH BIOTECHNOLOGIES: SWOT ANALYSIS
FIGURE 28 CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 CHARLES RIVER LABORATORIES: SWOT ANALYSIS
FIGURE 30 CYTIVA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 CYTIVA: SWOT ANALYSIS
FIGURE 32 NOVASEP: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 NOVASEP: SWOT ANALYSIS